RxDoctor Payments Data

Maxine Orris, MD

Internal Medicine · Brooklyn, NYNPI 1720040702

Payments from drug & device makers

$798in general payments, 2019–2025

Across 31 payments — averaging $25.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$204
  • AstraZeneca$125
  • Astellas Pharma US Inc$103
  • Novo Nordisk$75
  • Almatica Pharma LLC$67
  • Lilly USA, LLC$65
  • plus $158 from 6 others

What the payments were for

  • Food & beverage$798100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$798 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$6,639
Medicare patients
42
Services billed
78

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide147$193,406
JanuviaSitagliptin Phosphate174$142,083
JardianceEmpagliflozin104$96,745
OdefseyEmtricitab/Rilpiviri/Tenof Ala28$96,182
EliquisApixaban103$75,972
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate15$53,834
JanumetSitagliptin Phos/Metformin Hcl67$53,341
EntrestoSacubitril/Valsartan53$45,125
LinzessLinaclotide60$39,880
XareltoRivaroxaban52$38,346
Metformin Er GastricMetformin Hcl24$37,006
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog65$32,251
OzempicSemaglutide20$29,272
FarxigaDapagliflozin Propanediol48$28,513
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df18$26,712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$65$193,406147 claims
PfizerEliquis$19$75,972103 claims
AbbVieLinzess, Restasis$26$43,44971 claims
AstraZenecaFarxiga, Symbicort$125$35,93970 claims
Novo NordiskOzempic$75$29,27220 claims
GSKTrelegy Ellipta$44$15,83613 claims
Astellas Pharma US IncMyrbetriq$103$13,06115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →